Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | RAD52 | P43351 | 3/20 | 0.44 |
| ▸ | GFER | P55789 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30168583 | 1.00 | ATAD2 (0.55) | ATAD2NOTUMMAPTGAARAD52 | |
| SCHEMBL10493943 | 0.90 | ATAD2 (0.53) | ATAD2NOTUMMAPTGAARAD52 | |
| SCHEMBL3656320 | 0.86 | MAPT (0.49) | ATAD2NOTUMMAPTGAARAD52 | |
| SCHEMBL2267570 | 0.86 | HTR2A (0.45) | ATAD2NOTUMMAPTGAARAD52 | |
| Hydrochloric Acid SCHEMBL6844552 | 0.84 | HTR2A (0.44) | ATAD2NOTUMMAPTGAARAD52 | |
| SCHEMBL24077203 | 0.81 | HTR2A (0.46) | ATAD2MAPTGAARAD52GFER | |
| SCHEMBL3437431 | 0.80 | NOTUM (0.51) | NOTUMHRH3KDM4EALDH1A1MEN1 | |
| SCHEMBL18426670 | 0.80 | ATAD2 (0.43) | ATAD2NOTUMMAPTGAARAD52 | |
| SCHEMBL4005243 | 0.80 | NOS3 (0.46) | ATAD2MAPTGAARAD52GFER | |
| SCHEMBL15068983 | 0.79 | MAPT (0.47) | ATAD2MAPTGAARAD52GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357638-A1 | MONOAZO DICHROIC DYE COMPOUND, POLARIZING PLATE COMPOSITION COMPRISING SAME, POLARIZING PLATE FORMED THEREFROM, AND OPTICAL DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2023-11-09 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2021239885-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | WO | disclosed |
| EP-3856186-A1 | SMALL MOLECULE INHIBITORS OF DYRK1/CLK AND USES THEREOF | Arizona Board of Regents on behalf of the University of Arizona (US) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020069418-A1 | SMALL MOLECULE INHIBITORS OF DYRK1/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20120041207-A1 | Compound | STERIX LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| EP-2293122-A2 | Polarizing film, laminate, and liquid crystal display device | Fujifilm Corporation (JP) | 2011-03-09 | — | — | EP | disclosed |
| US-20110009448-A1 | Compound | STERIX LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-7786152-B2 | Compound | STERIX LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| EP-2141163-A1 | Substituted thiazolidinones, their production and utilisation as medicine | Bayer Schering Pharma AG (DE) | 2010-01-06 | — | — | EP | disclosed |
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | STERIX LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-7309715-B2 | Compound | STERIX LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| EP-1556040-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 | Sterix Limited (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20040143124-A1 | Compound | STERIX LIMITED (GB) | 2004-07-22 | — | — | US | disclosed |
| WO-2004037251-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 | STERIX LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
| EP-1181004-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES AND DYEING METHOD USING SAME | L'OREAL (FR) | 2002-02-27 | — | — | EP | disclosed |
| WO-2001066072-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES AND DYEING METHOD USING SAME | L'OREAL (FR) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | ATAD2 2496/4885NOTUM 2088/4885MAPT 1004/4885 |
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | HSD11B1, HSD3B1, HSD11B2 | ATAD2 3726/4885NOTUM 382/4885MAPT 4759/4885 |
| US-20110009448-A1 | Compound | NR4A1, GPR6, PRMT6 | ATAD2 3805/4885NOTUM 2137/4885MAPT 4794/4885 |
| US-20120041207-A1 | Compound | NR4A1, GPR6, PRMT6 | ATAD2 3805/4885NOTUM 2137/4885MAPT 4794/4885 |
| US-20040143124-A1 | Compound | NR4A1, CBR1, NR2C2 | ATAD2 3996/4885NOTUM 2440/4885MAPT 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.